GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates...
resTORbio halts clinical development of RTB101 in respiratory illness
resTORbio has announced plans to stop the clinical development of RTB101 in the prevention of clinically symptomatic respiratory illness (CSRI) after its Phase III PROTECTOR 1 clinical trial failed to meet the primary goal.
TRIKAFTA (elexacaftor, ivacaftor and tezacaftor) for the Treatment of Cystic Fibrosis
TRIKAFTA is the first triple combination therapy containing elexacaftor, ivacaftor, and tezacaftor indicated for the treatment of cystic fibrosis (CF) in people aged 12 years and above and having a F508del mutation and one minimal function mutation.
Seqster and La Jolla Institute of Immunology partner on asthma study
Seqster has signed a three-year licensing deal and partnership with La Jolla Institute of Immunology (LJI) to support the execution of a $6.9m Asthma study.
Boehringer begins enrolment in Phase II BALANCE-CF1 trial
Boehringer Ingelheim has enrolled the first patient in the Phase II BALANCE-CF study investigating an inhaled epithelial sodium channel (ENaC) inhibitor, BI 1265162, to treat cystic fibrosis.
Verona Pharma closes enrolment in Phase IIb COPD trial
UK-based biopharmaceutical firm Verona Pharma has completed patient enrolment in a Phase IIb clinical trial of nebulised ensifentrine (RPL554) to treat moderate-to-severe chronic obstructive pulmonary disease (COPD).
Nucala minimises exacerbations in eosinophilic asthma patients
GlaxoSmithKline (GSK) has reported positive results from its study of Nucala (mepolizumab) in patients with severe eosinophilic asthma.
AstraZeneca’s Breztri Aerosphere is a late-stage blockbuster
GlobalData anticipates rapid approval for AstraZeneca triple-combination therapy inhaler Breztri Aerosphere in the EU and US.
The most researched drugs in cystic fibrosis trials
GlobalData analysed the number of clinical trials examining cystic fibrosis with start dates between January 1, 2009 and August 28, 2019.
AstraZeneca’s ETHOS trial of Breztri Aerosphere meets primary endpoint
AstraZeneca has reported positive findings from the Phase III ETHOS trial that evaluated Breztri Aerosphere for the treatment of patients with severe chronic obstructive pulmonary disease (COPD).
Knopp begins study of dexpramipexole in eosinophilic asthma patients
Knopp Biosciences has commenced patient enrolment in a Phase II clinical trial of dexpramipexole for the treatment of moderate-to-severe eosinophilic asthma.